Literature DB >> 29685478

Postprandial endotoxemia may influence the development of type 2 diabetes mellitus: From the CORDIOPREV study.

Antonio Camargo1, Rosa Jimenez-Lucena1, Juan F Alcala-Diaz1, Oriol A Rangel-Zuñiga1, Sonia Garcia-Carpintero1, Javier Lopez-Moreno1, Ruth Blanco-Rojo1, Javier Delgado-Lista1, Pablo Perez-Martinez1, Ben van Ommen2, Maria M Malagon3, Jose M Ordovas4, Francisco Perez-Jimenez1, Jose Lopez-Miranda5.   

Abstract

BACKGROUND & AIMS: Insulin resistance (IR) and impaired beta-cell function are key determinants of type 2 diabetes mellitus (T2DM). Intestinal absorption of bacterial components activates the toll-like receptors inducing inflammation, and this in turn IR. We evaluated the role of endotoxemia in promoting inflammation-induced insulin resistance (IR) in the development of T2DM, and its usefulness as predictive biomarker.
METHODS: We included in this study 462 patients from the CORDIOPREV study without T2DM at baseline. Of these, 107 patients developed T2DM according to the American Diabetes Association (ADA) diagnosis criteria after a median follow-up of 60 months (Incident-DIAB group), whereas 355 patients did not developed it during this period of time (Non-DIAB group).
RESULTS: We observed a postprandial increase in lipopolysaccharides (LPS) levels in the Incident-DIAB at baseline (P < 0.001), whereas LPS levels were not modified in the Non-DIAB. Disease-free survival curves based on the LPS postprandial fold change improved T2DM Risk Assessment as compared with the previously described FINDRISC score (hazard ratio of 2.076, 95% CI 1.149-3.750 vs. 1.384, 95% CI 0.740-2.589). Moreover, disease-free survival curves combining the LPS postprandial fold change and FINDRISC score together showed a hazard ratio of 3.835 (95% CI 1.323-11.114), linked to high values of both parameters.
CONCLUSION: Our results suggest that a high postprandial endotoxemia precedes the development of T2DM. Our results also showed the potential use of LPS plasma levels as a biomarker predictor of T2DM development. CLINICAL TRIALS.GOV. IDENTIFIER: NCT00924937.
Copyright © 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  CORDIOPREV; Diabetes; Endotoxemia; Inflammation; Prediction model

Mesh:

Year:  2018        PMID: 29685478     DOI: 10.1016/j.clnu.2018.03.016

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  10 in total

1.  Mulberroside A from Cortex Mori Enhanced Gut Integrity in Diabetes.

Authors:  Yinyan Xu; Hengli Guo; Tingting Zhao; Jing Fu; Youhua Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-20       Impact factor: 2.629

2.  Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study.

Authors:  Manuel D Gahete; Mercedes Del Rio-Moreno; Antonio Camargo; Juan F Alcala-Diaz; Emilia Alors-Perez; Javier Delgado-Lista; Oscar Reyes; Sebastian Ventura; Pablo Perez-Martínez; Justo P Castaño; José Lopez-Miranda; Raul M Luque
Journal:  EBioMedicine       Date:  2018-11-13       Impact factor: 8.143

3.  Hepatic expression of lipopolysaccharide-binding protein (Lbp) is induced by the gut microbiota through Myd88 and impairs glucose tolerance in mice independent of obesity.

Authors:  Antonio Molinaro; Ara Koh; Hao Wu; Marc Schoeler; Maria Ilaria Faggi; Alba Carreras; Anna Hallén; Fredrik Bäckhed; Robert Caesar
Journal:  Mol Metab       Date:  2020-04-16       Impact factor: 7.422

Review 4.  Whole Alga, Algal Extracts, and Compounds as Ingredients of Functional Foods: Composition and Action Mechanism Relationships in the Prevention and Treatment of Type-2 Diabetes Mellitus.

Authors:  Aránzazu Bocanegra; Adrián Macho-González; Alba Garcimartín; Juana Benedí; Francisco José Sánchez-Muniz
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

5.  An altered microbiota pattern precedes Type 2 diabetes mellitus development: From the CORDIOPREV study.

Authors:  Cristina Vals-Delgado; Juan F Alcala-Diaz; Helena Molina-Abril; Irene Roncero-Ramos; Martien P M Caspers; Frank H J Schuren; Tim J Van den Broek; Raul Luque; Pablo Perez-Martinez; Niki Katsiki; Javier Delgado-Lista; Jose M Ordovas; Ben van Ommen; Antonio Camargo; Jose Lopez-Miranda
Journal:  J Adv Res       Date:  2021-05-13       Impact factor: 10.479

Review 6.  Gut-Microbial Metabolites, Probiotics and Their Roles in Type 2 Diabetes.

Authors:  Lixiang Zhai; Jiayan Wu; Yan Y Lam; Hiu Yee Kwan; Zhao-Xiang Bian; Hoi Leong Xavier Wong
Journal:  Int J Mol Sci       Date:  2021-11-27       Impact factor: 5.923

7.  Improvement of intestinal barrier function, gut microbiota, and metabolic endotoxemia in type 2 diabetes rats by curcumin.

Authors:  Jingze Huang; Binbin Guan; Lijing Lin; Yanping Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Dietary Intervention Modulates the Expression of Splicing Machinery in Cardiovascular Patients at High Risk of Type 2 Diabetes Development: From the CORDIOPREV Study.

Authors:  Mercedes Del Río-Moreno; Raúl M Luque; Oriol A Rangel-Zúñiga; Emilia Alors-Pérez; Juan F Alcalá-Diaz; Irene Roncero-Ramos; Antonio Camargo; Manuel D Gahete; José López-Miranda; Justo P Castaño
Journal:  Nutrients       Date:  2020-11-17       Impact factor: 5.717

9.  Helminth Mediated Attenuation of Systemic Inflammation and Microbial Translocation in Helminth-Diabetes Comorbidity.

Authors:  Anuradha Rajamanickam; Saravanan Munisankar; Pradeep A Menon; Chandrakumar Dolla; Thomas B Nutman; Subash Babu
Journal:  Front Cell Infect Microbiol       Date:  2020-08-31       Impact factor: 5.293

10.  A plasma fatty acid profile associated to type 2 diabetes development: from the CORDIOPREV study.

Authors:  Alejandro Villasanta-Gonzalez; Juan Francisco Alcala-Diaz; Antonio Camargo; Jose Lopez-Miranda; Cristina Vals-Delgado; Antonio Pablo Arenas; Magdalena P Cardelo; Juan Luis Romero-Cabrera; Fernando Rodriguez-Cantalejo; Javier Delgado-Lista; Maria M Malagon; Pablo Perez-Martinez; Matthias B Schulze
Journal:  Eur J Nutr       Date:  2021-10-05       Impact factor: 5.614

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.